Antibodies inhibit hyperactive protein disposal
A system of ubiquitin-associated enzymes marks misfolded or needless proteins for degradation to maintain protein homeostasis, but its dysfunction can lead to disease. Hyperactivation of the E3 ubiquitin ligase carboxyl-terminus of Hsp70-interacting protein, or CHIP, is linked to cystic fibrosis, neurodegeneration and cancer. Scientists confront numerous challenges when attempting to inhibit CHIP due to its complex interaction network with E2 ubiquitin-conjugating enzymes and chaperones, so that CHIP can orchestrate ubiquitin transfer to the substrate. CHIP has a dimeric structure and uses its tetratricopeptide repeat, or TPR, domain to bind chaperones and a U-box domain to bind the E2 enzyme.

In a recent Journal of Biological Chemistry article, Dong hee Chung, Emily Connelly and a team at the University of California, San Francisco, used a biopanning platform for screening inhibitors of CHIP. This technique involved a phage display library of fragment antigen-binding antibodies, or Fabs, segments of a full antibody able to penetrate tissues, and rounds of filtering for CHIP binders. The researchers identified six Fabs for further characterization.
The authors performed fluorescence polarization assays to examine whether the Fabs inhibited binding of a model peptide substrate to the CHIP TPR domain. They also assessed the ability of each Fab to inhibit Hsp70 chaperone ubiquitination by CHIP. The Fab 2F1 stood out because of its strong inhibition of both peptide binding and Hsp70 ubiquitination. Using cryogenic electron microscopy, the researchers determined that two 2F1 molecules bind to the CHIP dimer, one at each U-box domain.
The authors suggested that 2F1 and the other Fabs in this study will provide useful tools for scientists to probe the various CHIP domains and substrate interactions. Inhibiting individual aspects of CHIP function will also help scientists gauge the value of CHIP as a potential drug target.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Building a career in nutrition across continents
Driven by past women in science, Kazi Sarjana Safain left Bangladesh and pursued a scientific career in the U.S.

Avoiding common figure errors in manuscript submissions
The three figure issues most often flagged during JBC’s data integrity review are background signal errors, image reuse and undeclared splicing errors. Learn how to avoid these and prevent mistakes that could impede publication.

Ragweed compound thwarts aggressive bladder and breast cancers
Scientists from the University of Michigan reveal the mechanism of action of ambrosin, a compound from ragweed, selectively attacks advanced bladder and breast cancer cells in cell-based models, highlighting its potential to treat advanced tumors.

Lipid-lowering therapies could help treat IBD
Genetic evidence shows that drugs that reduce cholesterol or triglyceride levels can either raise or lower inflammatory bowel disease risk by altering gut microbes and immune signaling.

Key regulator of cholesterol protects against Alzheimer’s disease
A new study identifies oxysterol-binding protein-related protein 6 as a central controller of brain cholesterol balance, with protective effects against Alzheimer’s-related neurodegeneration.

From humble beginnings to unlocking lysosomal secrets
Monther Abu–Remaileh will receive the ASBMB’s 2026 Walter A. Shaw Young Investigator Award in Lipid Research at the ASBMB Annual Meeting, March 7-10 in Washington, D.C.